High Times
Home > Boards > US Listed > Biotechs >

Neptune tech and Bio-Resources (NEPT)

Add NEPT Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 10/18/2018 5:06:28 PM - Followers: 41 - Board type: Free - Posts Today: 0


I first heard about this stock when it was trading at the $2.32 mark a few weeks ago. Now we're hearing that more institutional buying and high profile firms are getting ready to take positions. That, in-turn, should lead to even more buying by retail investors. It's the stock snowball and visibility effect and this company deserves it 

About Neptune

Neptune Technologies & Bioressources Inc. researches, develops and commercializes proprietary bioactive ingredients and products with superior added-value and clinically proven health benefits. The Company extracts a range of bioactive ingredients such as novel proprietary omega-3 phospholipids from abundant yet underexploited marine biomass including Krill, a cold deep water zooplankton. Neptune's first commercially available product is Neptune Krill Oil (NKO®), which represents the only clinically proven and scientifically acknowledged marine omega-3 phospholipids with cardiovascular, cognitive and anti-inflammatory benefits for human applications and which exhibits unmet safety, purity and stability and consequently denoting a new level of excellence in omega-3 standards.

Neptune is pursuing market opportunities in the nutraceutical market including dietary supplements and functional foods. The Company is benefiting from opportunities in the pharmaceutical market through its pharmaceutical subsidiaries Acasti Pharma and NeuroBioPharm (including medical food, over-the-counter and prescription drug applications).

The Mission of Neptune is to:

  • Research, Develop and Commercialize Novel Marine Bioactive Ingredients
  • Pursue opportunities in the nutraceutical markets
    • Dietary Supplement
    • Functional Food
  • Exploit pharmaceutical applications
    • Subsidiary Acasti Pharma Inc: Cardiovascular diseases
    • Subsidiary NeuroBioPharm Inc.: Neurodegenerative diseases
  • Validate Superiority, Safety & Effectiveness
  • Protect Intellectual Property
  •   Enter Commercialization Alliances and Partnership Licenses

Promising results from A new cholesterol drug have helped call attention to Neptune, which is aiming for cholesterol/hyperlipidemia's ultimate prize, but unlike most companies dealing with clinical studies and regulatory approvals, Neptune is a revenue generating company whose products are already marketed and distributed in over 20 countries worldwide.

The Versant Partners' report, subtitled: "Krill oil franchise poised to outperform in multiple consumer and medical markets" features a few key points of note.

With NEPT's fiscal year end being February, Mr. Loe is calling for:

* F2012 revenues of $21.79 million and earnings $4.34 million ($0.09 EPS)
* F2013 revenues of $32.39 million and earnings of $8.81 million ($0.17 EPS)
* F2014 revenues of $45.37 million and earnings of $15.69 million ($0.30 EPS)
Loe cited management plans to meet forecasted demand by increasing current plant production from 130 thousand kilograms of krill oil per year to 430 thousand kilograms per year by 2015, a 300% production increase.
The report pinned its share price targets not only on the business Neptune has in hand, but also its future. By far, the biggest foundation Mr. Loe constructed on which to base his conclusions came from his meticulous research into the product itself - Neptune Krill Oil or NKO as it is branded on the market - and all its further refined products, such as Acasti's drug candidate called 'CaPre'.

Along the way, Loe also gives a significant nod to the functional food alliances Neptune developed with Yoplait - which is 50% owned by General Mills - and the food manufacturing behemoth, Nestle.

Mr. Loe wrote that both Yoplait and Nestle "should conclude development," of their research into Neptune Krill Oil by the end of the current year and that assuming all goes well, the sales of krill-oil infused food products by these giants would be a major revenue driver for Neptune in 2013/14  About Acasti

Acasti Pharma is developing safe and effective pharmaceutical and medical applications with an initial focus on cardiovascular disease by leveraging the intellectual property, clinical data and know how developed by Neptune Technologies. The Company is advancing a portfolio of bioactive ingredients of proprietary novel omega-3 phospholipids through the pharmaceutical development pathway which includes prescription medical foods (MF), over-the-counter products (OTC), and prescription drugs (Rx). Phospholipids are the major component of cell membranes and essential for all vital cell processes. They are one of the principle constituents of High Density Lipoprotein (good cholesterol) and play, as such, an important role in modulating cholesterol efflux.

Acasti Pharma's proprietary novel phospholipids carry and functionalize the polyunsaturated omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) stabilized by potent antioxidants. Evidence has demonstrated the anti-inflammatory properties of EPA and DHA regulating important biological functions including degenerative, arthritic, circulatory, digestive, and brain diseases. Delivering omega-3s functionalized on phospholipids helps optimize the omega-3 fatty acid therapeutic benefits. Potent antioxidants contribute to proper physiological regulation preventing free radical cellular damage, a common pathway for cardiovascular disease and inflammation as well as neurodegenerative disease 


High Times
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
NEPT News: CBD Exploding into Mainstream Wellness Products 10/11/2018 08:45:00 AM
NEPT News: Report of Foreign Issuer (6-k) 09/27/2018 09:55:15 AM
NEPT News: Nomination de Caroline Lavoie au poste de directrice des affaires corporatives 09/27/2018 08:37:00 AM
NEPT News: Appointment of Caroline Lavoie, Director of Corporate Affairs 09/27/2018 08:32:00 AM
NEPT News: Appointment of Caroline Lavoie, Director of Corporate Affairs 09/27/2018 08:32:00 AM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#311   Health Canada Approval, expected any day now!! Cryptotrademomo 10/18/18 05:06:28 PM
#310   Looking very strong among the weakness. brimkelly 10/16/18 11:40:43 AM
#309   New HOD :) $NEPT r1aviator 10/15/18 03:18:00 PM
#308   ‘tis the season! $NEPT r1aviator 10/15/18 10:32:12 AM
#307   I think your right, seems to be :) Mototeam 10/15/18 10:30:28 AM
#306   She wants to break out. jmo :) $NEPT r1aviator 10/15/18 10:07:28 AM
#305   The day is young..we still may gain ;) $NEPT r1aviator 10/11/18 10:41:50 AM
#304   My sources were incorrect. My apologies FunkPhilosopher 10/10/18 09:09:38 PM
#303   Been watching a couple months now. CEO will FunkPhilosopher 10/10/18 04:47:08 PM
#302   Right on, just wanted to see the board Mototeam 10/10/18 10:25:08 AM
#301   Waiting with you all. Been here yr. more fuzzychin 10/10/18 09:27:53 AM
#300   Fine by be! $NEPT r1aviator 10/10/18 09:00:52 AM
#299   No kidding. This Stock is gonna blow up Mototeam 10/10/18 07:54:09 AM
#298   Quiet board for what’s happening.. $NEPT r1aviator 10/08/18 02:17:35 PM
#297   Loaded today adtime 10/04/18 05:27:26 PM
#296   ~$600k on-bid $NEPT r1aviator 10/04/18 01:43:24 PM
#295   major-league bids $NEPT r1aviator 10/04/18 01:34:26 PM
#294   Took a starter $NEPT r1aviator 10/04/18 12:51:40 PM
#293   I think that this dip is going to Mototeam 10/04/18 11:21:54 AM
#292   it's quiet in here Mototeam 10/04/18 11:20:13 AM
#291   Invested 50K today nept$4.05going to Neptune growing greene weedtrader420 10/02/18 01:22:17 AM
#290   5.10 post market slyguy8888 10/01/18 05:43:47 PM
#289   * * $NEPT Video Chart 10-01-18 * * ClayTrader 10/01/18 05:24:46 PM
#288   $NEPT buy the dip!!! Bullish!! akmj 10/01/18 03:19:24 PM
#287   NEPT WE HAVE A KICKER BUY BUY Hey Ray 10/01/18 12:05:00 PM
#286   $NEPT Neptune Receives Confirmation of Readiness Letter Cryptotrademomo 09/29/18 10:20:29 AM
#285   NEWS OUT!! https://www.ftmig.com/cannabis-marijuana/appointment-of-caroline-lavo Jdoggg 09/27/18 10:14:48 AM
#284   $NEPT $CGC #HEALTHCANADA #NEWS Appt of Caroline Lavoie, Cryptotrademomo 09/27/18 09:22:14 AM
#283   $NEPT Activist Investor 13D FILING Cryptotrademomo 09/26/18 06:10:48 PM
#282   * * $NEPT Video Chart 09-19-18 * * ClayTrader 09/19/18 06:31:52 PM
#281   NEPT nice news this AM. cjstocksup 09/17/18 08:15:50 AM
#280   Source? micar 09/10/18 01:30:00 PM
#279   Neptune on sale today get it while you weedtrader420 09/10/18 09:47:59 AM
#278   Neptune $15 Target price smoking a cron joint weedtrader420 09/10/18 09:42:26 AM
#277   Neptune Announces First Quarter Results JohnCM 09/10/18 08:01:12 AM
#276   $NEPT Cannabis Business Cryptotrademomo 09/08/18 08:09:28 AM
#275   Neptune Announces Multi-year Agreement with Canopy Growth to Cryptotrademomo 09/05/18 07:41:19 PM
#274   Neptune Technologies: Ties To Canopy Growth Corp. Offer Cryptotrademomo 09/05/18 07:39:35 PM
#273   Lets hope this stock keeps rising! After 6 losing money here 09/04/18 02:32:29 PM
#272   NEPT has been holding it's recent gains very RLBTrader 08/31/18 05:15:52 PM
#271   $10 Target price Contract with canopy growth doing weedtrader420 08/31/18 08:37:47 AM
#270   Great day. SuperDuty350 08/24/18 10:43:43 AM
#269   NEPT will test 3.40s today.many big deals are mojo joyo 08/21/18 08:45:30 AM
#268   Looks like bulls are taking over now.some good mojo joyo 08/20/18 12:52:24 PM
#267   Take a bite of both N.J. and mojo joyo 08/20/18 10:38:22 AM
#266   What does NEPT have to do to be Joe_NY 08/20/18 10:32:54 AM
#265   N.Y is about legalize , new jersey is mojo joyo 08/20/18 08:47:43 AM
#264   What’s going on in ny and nj with Joe_NY 08/19/18 01:35:04 PM
#263   FWIW NEPT.TO shot to the moon, and then had dr_airtime 08/15/18 10:09:39 AM
#262   This will be 6 to 8 dollars soon mojo joyo 08/10/18 07:37:50 PM